October 2006
ICIS Chemical Business;10/16/2006, Vol. 1 Issue 39, p37
Trade Publication
The article presents updates on the research and development in the chemical industry. UVPS Environmental Solutions, a spin-off from The Robert Gordon University in Aberdeen, Scotland, has developed a process to remove 100% of contaminants from industrial waste discharges. ABN AMRO Capital Life Sciences has led a €22m ($28m) funding of Amsterdam Molecular Therapeutics, which specialises in gene therapies to treat serious inherited, metabolic or central nervous disorders.


Related Articles

  • AMT GETS EUR 1.8 MILLION FOR EX VIVO GENE FOR CROHN'S.  // Worldwide Biotech;Nov2003, Vol. 15 Issue 11, p1 

    Reports on the subsidy received by Amsterdam Molecular Therapeutics BV from the Dutch Ministry of Economic Affairs for the pre-clinical development of ex vivo gene therapy.

  • Financings Roundup.  // BioWorld Today;1/5/2012, Vol. 23 Issue 3, p7 

    The article reports on a 2.5 million euros invested by venture capitals in Amsterdam Molecular Therapeutics (AMT) to enable the company to stay solvent long enough to close a deal for its gene therapy treatment for hemophilia B.

  • AMT Prepares for Glybera's Phase III Extension Study. Moran, Nuala // BioWorld Today;9/2/2011, Vol. 22 Issue 171, p1 

    The article reports on the preparation of Amsterdam Molecular Therapeutics (AMT) NV for Phase III extension study of Glybera, its gene therapy treatment for lipoprotein lipase deficiency. Details of the Phase III trail are given. It cites that the company is awaiting approval from the European...

  • OTHER NEWS TO NOTE.  // BioWorld International;12/5/2007, Vol. 12 Issue 49, p3 

    This section offers news briefs concerning the U.S. biotechnology sector. The right to commercialize gene therapy products was licensed by Amsterdam Molecular Therapeutics from Digna Biotech SL. The pre-clinical studies of ANAVEX 1-41, the lead drug candidate of Anavex Life Sciences Corp. for...

  • Amsterdam Molecular Raises €50M In IPO For Gene Therapies. Shrine, Jim // BioWorld Today;6/21/2007, Vol. 18 Issue 120, p1 

    The article reports that Dutch company Amsterdam Molecular Therapeutics Holding BV (AMT) has produced a €50 million in an initial public offering (IPO) to fund development of its gene-based therapies for orphan diseases. AMT sold 5 million shares at €10 per share. The shares, under...

  • CLINIC ROUNDUP.  // BioWorld Today;3/11/2010, Vol. 21 Issue 47, p4 

    This section offers news briefs related to clinical trials. AM-Pharma BV released results from its acute kidney injury trial that shows improved renal function using alkaline phosphatase. Amsterdam Molecular Therapeutics used its Phase I/II exploratory trial gene therapy product for hemophilia B...

  • EMA Issues Negative Opinion for AMT's Gene Therapy. Moran, Nuala // BioWorld Today;6/27/2011, Vol. 22 Issue 123, p3 

    The article focuses on the negative opinion issued by the European Medicines Agency (EMA) on the gene therapy Glybera developed by Amsterdam Molecular Therapeutics NV. The EMA has rejected Glybera as a treatment for lipoprotein lipase deficiency at present. Company chief executive officer...

  • AMT Gets $3.2M Runway, Aims For Hemophilia Gene Therapy. Moran, Nuala // BioWorld International;1/4/2012, Vol. 17 Issue 1, p1 

    This article reports on the 2.5 million euros fund given by venture capital investors in Amsterdam Molecular Therapeutics (AMT) to enable the company to stay solvent until it close a deal for its gene therapy treatment for hemophilia B. The treatment is the first gene therapy to reduce bleeding...

  • Rasi Breaks EMA's Silence on Glybera, Transparency Issues. Sheridan, Cormac // BioWorld International;3/7/2012, Vol. 17 Issue 10, p1 

    The article reports that Guido Rasi, the newly appointed director general of the European Medicines Agency (EMA), claims that the difference in opinion between the EMA's Committee for Human Medicinal Products (CHMP) and its Committee for Advanced Therapeutics (CAT), on the dossier for gene...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics